Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 5/20 | 0.46 |
| ▸ | NPC1 | O15118 | 5/20 | 0.46 |
| ▸ | RAB9A | P51151 | 4/20 | 0.46 |
| ▸ | SMO | Q99835 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5460915 | 0.90 | MAPT (0.48) | KMT2AMEN1ALDH1A1MAPTNPC1 | |
| SCHEMBL5473493 | 0.88 | CYP1A2 (0.46) | MAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL5458255 | 0.83 | ALDH1A1 (0.53) | HSD17B10KMT2AMEN1ALDH1A1MAPT | |
| SCHEMBL5459980 | 0.83 | GFER (0.62) | HSD17B10KMT2AMEN1ALDH1A1MAPT | |
| SCHEMBL5467429 | 0.82 | MAPT (0.48) | ALDH1A1MAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL5460590 | 0.82 | MAPT (0.52) | KMT2AMEN1ALDH1A1MAPTNPC1 | |
| SCHEMBL5462265 | 0.81 | MAPT (0.48) | KMT2AMEN1ALDH1A1MAPTNPC1 | |
| SCHEMBL5456044 | 0.80 | GFER (0.46) | HSD17B10KMT2AMEN1ALDH1A1MAPT | |
| SCHEMBL5458362 | 0.80 | RAB9A (0.58) | KMT2AMEN1ALDH1A1MAPTNPC1 | |
| SCHEMBL5460786 | 0.79 | MAPT (0.48) | HSD17B10ALDH1A1MAPTNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070249620-A1 | Urea Derivative | SANKYO COMPANY, LIMITED (JP) | 2007-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249620-A1 | Urea Derivative | UGP2, SLC14A1, DGAT1 | HSD17B10 854/4885KMT2A 1350/4885MEN1 1828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.